To elucidate the precise physiological regulation of FGF-23, we characterized the mouse FGF-23 5Ј-flanking region and analyzed its promoter activity. The 5Ј-flanking region of the mouse FGF-23 gene contained a TFIID site (TATA box) and several putative transcription factor binding sites, including MZF1, GATA-1 and c-Ets-1 motifs, but it did not contain the typical sequences of the vitamin D response element. Plasmids encoding 554-bp (pGL/Ϫ0.6), 364-bp (pGL/Ϫ0.4) and 200-bp (pGL/Ϫ0.13) promoter regions containing the TFIID element and ϩ1-bp fragments drove the downstream expression of a luciferase reporter gene in transfection assays. We also found that FGF-23 mRNA was expressed in K-562 erythroleukemia cell lines but not in MC3T3-E1, Raji, or Hep G2 human carcinoma cells. Treatment with 1,25-dihydroxyvitamin D 3 in the presence of high phosphate markedly stimulated pGL/Ϫ0.6 activity, but calcium had no effect. In addition, the plasma FGF-23 levels were affected by the dietary and plasma inorganic phosphate concentrations. Finally, the levels of plasma FGF-23 in vitamin D receptor-null mice were significantly lower than in wild-type mice. The presents study demonstrated that vitamin D and the plasma phosphate level are important regulators of the transcription of the mouse FGF-23 gene. gene regulation; vitamin D receptor; phosphate homeostasis THE HOMEOSTASIS OF PLASMA PHOSPHATE is essential for many biological processes, including skeletal mineralization and energy metabolism. Recent investigations of diseases with abnormal phosphate homeostasis have revealed circulating phosphaturic hormones, collectively called phosphatonin (6, 23). Common clinical features, including hypophosphatemia resulting from renal phosphate wasting and impaired mineralization of bone are shared by X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and autosomal-dominant hypophosphatemic rickets (ADHR; see Refs. 28, 31, and 32) , and the presence of a phosphatonin has been suspected in patients with these diseases because their plasma calcium and parathyroid hormone (PTH) levels are usually normal (8, 9) .
THE HOMEOSTASIS OF PLASMA PHOSPHATE is essential for many biological processes, including skeletal mineralization and energy metabolism. Recent investigations of diseases with abnormal phosphate homeostasis have revealed circulating phosphaturic hormones, collectively called phosphatonin (6, 23) . Common clinical features, including hypophosphatemia resulting from renal phosphate wasting and impaired mineralization of bone are shared by X-linked hypophosphatemic rickets (XLH), tumor-induced osteomalacia (TIO), and autosomal-dominant hypophosphatemic rickets (ADHR; see Refs. 28, 31, and 32) , and the presence of a phosphatonin has been suspected in patients with these diseases because their plasma calcium and parathyroid hormone (PTH) levels are usually normal (8, 9) .
Genetic studies of ADHR and TIO have identified fibroblast growth factor (FGF)-23 as a likely candidate for phosphatonin (28, 31) . In addition, continuous exposure to recombinant FGF-23 reproduces hypophosphatemic osteomalacia and the inappropriately low plasma levels of 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ; see Ref. 28] . Also, a mutant form of FGF-23 (FGF-23R179Q), which is derived from disease-causing missense mutations of ADHR, is resistant to proteolytic processing that normally converts the biologically functional full-length polypeptide into inactive fragments (3, 33) . Furthermore, elevated circulatory levels of FGF-23 occur not only in patients with TIO but also in those with XLH (35) . These findings indicate that excess FGF-23 activity causes the hypophosphatemia and impaired mineralization of bone that is associated with phosphatonin (6, 21) .
In a previous study, we demonstrated that the mutant FGF-23 suppressed the type IIa sodium-dependent phosphate (Na-P i ) cotransport activity in the kidney and the small intestine. We also showed that the mutant FGF-23 reduced the amount of plasma 1␣,25-dihydroxyvitamin D (1␣-OHase) independent of PTH action. Furthermore, FGF-23 decreased renal 1␣-OHase mRNA and also increased 25-hydroxyvitamin D-24-hydroxylase (24-OHase) expression (22, 25) . Interestingly, mutant mice lacking FGF-23 exhibit severe hyperphosphatemia, with enhanced renal phosphate reabsorption, severe growth retardation with abnormal bone phenotype, and a markedly shortened life span (27) . They also have an elevation in plasma 1,25(OH) 2 D 3 that is the result of the enhanced expression of renal 1␣-OHase. In addition, recent studies have indicated that FGF-23 caused a reduction in plasma 1,25(OH) 2 D 3 because of the decreased expression of renal 1␣-OHase and increased expression of renal 24-OHase (26) . Collectively, these findings further support the idea that FGF-23 acts physiologically to reduce plasma phosphate and 1,25(OH) 2 D 3 levels.
Recent advances have led to a better understanding of the function of FGF-23. The largely based RT-PCR analysis suggests that FGF-23 is produced in liver, lymph nodes, thymus, heart, K-562, and Raji cell lines (28, 31, 34) . In a recent report, Liu et al. (16) demonstrated that bone is the predominant tissue for FGF-23 products. However, it is still unclear whether FGF-23 expression is regulated by 1,25(OH) 2 D 3 , PTH, calcitonin, plasma calcium, and plasma phosphate. In the current report, we show that the FGF-23 promoter is activated in the erythroleukemia cell line K-562 and regulated by 1,25(OH) 2 D 3 and plasma phosphate.
MATERIALS AND METHODS
Animals and diet. Vitamin D receptor (VDR) (Ϫ/Ϫ) mice were generated by gene targeting as previously described (10, 36) . VDR genotypes were confirmed by analyzing the DNA obtained from each mouse ϳ3 wk after birth. Genomic DNA was extracted from a tail clipping and amplified by PCR using primers specific for VDR (ϩ/ϩ) exon 2 or the neomycin resistance gene, as described previously (24) . VDR(ϩ/ϩ) and VDR(Ϫ/Ϫ) mice were weaned at 3 wk of age and given free access to water and a control diet containing 0.5% phosphate and 0.5% calcium for 5 wk (24) . Male C57BL mice were purchased from SLC (Shizuoka, Japan) and housed in plastic cages. The 6-wk-old animals were fed standard mouse chow (Oriental, Osaka, Japan) ad libitum for the 1st wk. After this period, they received a diet containing 0.6% calcium and 0.6% phosphate for 5 days. On the 6th day, three groups of six mice each were established: a control phosphate group, which was fed a diet containing 0.6% phosphate; a low-phosphate group, which was fed a diet containing 0.02% phosphate; and a high-phosphate group, which was fed a diet containing 1.2% phosphate. After 7 days of diet administration, all mice were used for the experiments.
Cell culture. Human chronic myelogenous leukemia K-562 cells, human hepatocarcinoma cells (Hep G2), human burkit lymphoma cells (Raji), and MC3T3-E1 cells derived from mouse calvaria were obtained from the RIKEN Bioresource Center (Tokyo, Japan). K-562 and Raji cells were cultured in Ham's F-12 medium (Sigma) supplemented with 10% FCS (Daiichi Pure Chemicals, Tokyo, Japan), 2 mM L-glutamine (Sigma Chemical, St. Louis, MO), and antibiotics (penicillin/streptomycin; Invitrogen, Carlsbad, CA) for growth media. Hep G2 and MC3T3-E1 cells were cultured in DMEM (Invitrogen) supplemented with 10% FCS and 2 mM L-glutamine and antibiotics. Subcultivations were performed every 3-4 days. All cell cultures were kept at 37°C in a humidified environment (5% CO 2-95% air). For the experiments of 1,25(OH)2D3 and other hormones, FCS was replaced with charcoal-treated FCS to remove endogenous steroids. Phosphate-free DMEM (Invitrogen) was used for phosphate concentration experiments.
Isolation of the promoter region of the mouse FGF-23 gene. To characterize the promoter region of the FGF-23 gene, we performed a BLAST search in GenBank (nr database http://www.ncbi.nlm.nih. gov/BLAST/) using a segment of DNA encompassing the FGF-23 promoter region on chromosome 6 (GenBank accession no. NT_039356) as a probe. The mouse FGF-23 genes were cloned by PCR using genomic DNA isolated from the mouse kidney, the primers listed in Table 1 , and pfu polymerase (Promega, Madison, WI). The PCR amplifications were performed using primers pro1 and pro7 as follows: 3 min at 94°C; followed by 25 cycles of 94°C for 30 s, 63°C for 30 s, and 72°C for 90 s; and a final extension at 72°C for 3 min. The amplification products were detected on a 0.8% agarose gel and visualized by ethidium bromide staining. PCR products Ͻ2 kb were purified and subcloned into pCR2.1. Genomic FGF-23 promoter regions were sequenced by an automated dye termination method (Amersham Biosciences, Piscataway, NJ).
PCR analysis to detect FGF-23 expression in cells. Total mRNA was purified using Isogen reagent (Wako Pure Chemicals, Tokyo, Japan) from K-562, Raji, and Hep G2 cells cultured in growth media. RT-PCR was performed using total RNA and the RT system from a first-strand synthesis kit (Invitrogen) according to the manufacturer's protocol. The cDNA generated was used for nested PCR along with human FGF-23-specific primers ( Table 2 ). The first PCR was carried out as follows: initial melting for 3 min at 94°C; followed by 20 cycles of 30 s at 94°C, 30 s at 50°C, and 30 s at 72°C; and a final extension for 3 min at 72°C. A second PCR, using the first PCR products (1:100 diluted) as a template and the second set of PCR primers, was performed to detect FGF-23 as follows: initial melting for 3 min at 94°C; followed by 30 cycles of 30 s at 94°C, 30 s at 55°C, and 30 s at 72°C; and a final extension step for 3 min at 72°C. The amplification products were detected on a 1.5% agarose gel. All PCR fragments were subcloned into the pCR2.1 vector (Invitrogen), and the expected amplification products were confirmed by sequencing. The position of the primers and the expected size of the amplification product from the FGF-23 mRNA is shown in Fig. 2A . As an internal control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified using the following primers: 5Ј-CTGCACCACCAACTGCTTAGC-3Ј (forward) and 5Ј-GCCTGCTTCACCACCTCTTG-3Ј (reverse).
Construction of reporter plasmids. The reporter plasmids used in this study were derived from the pGL3-Basic vector (Promega), which contains the firefly luciferase reporter gene. The mouse FGF-23 promoter-reporter constructs pGL/Ϫ1.4, pGL/Ϫ0.9, pGL/Ϫ0.6, pGL/ Ϫ0.4, pGL/Ϫ0.13, and pGL/ϩ1 were generated by PCR followed by digestion with restriction enzymes. A 1,430-bp genomic fragment was amplified by PCR from the 2,000-bp subfragment using an antisense primer starting at bp Ϫ1,403 (pro2, see Table 1 ) and a sense primer starting at bp ϩ98 (pro6) on the FGF-23 gene. The fragment was digested with KpnI and HindIII, subcloned into KpnI/HindIII-digested pBluescript SK Ϫ to create pB1430, and sequenced. To generate the luciferase reporter gene construct pGL/Ϫ1.4, the insert was excised from pB1430 with KpnI and HindIII within the primer sequence and then subcloned into the KpnI/HindIII-digested pGL3 basic vector to create pGL/Ϫ1.4. The gene constructs pGL/Ϫ0.9, pGL/Ϫ0.4, pGL/ Ϫ0.3, and pGL/ϩ1 were generated by PCR with a sense primer (pro3, pro4, pro10, or pro9) and antisense primer pro6. These fragments were also subcloned in the same way as pGL/Ϫ1.4 into the pBluescript SK Ϫ and pGL3 basic vectors. A 554-bp and a 128-bp genomic DNA fragment were generated by enzyme digestion of pB1430 within the primer using HindIII or within the genome sequences using SacI. These fragments were subcloned into SacI/HindIII-digested pGL3 basic vector and sequenced on both strands. The 3Ј-end of all constructs ends at bp ϩ98 bp in the mouse FGF-23 gene. We used the PCR to delete the sequence of the TATA-like box (pGL/⌬TATA) with primer pro13 and a M13 primer RV (5Ј-CAGGAAACAGCTAT-GAC-3Ј: Takara Bio, Tokyo, Japan) from the pBluescript SK Ϫ vector. The PCR fragment was inserted in pGL/Ϫ128 with SmaI-digested plasmid. For the pGL/⌬MC construct in which the C-Ets-1 and MZF1 motifs were deleted, we performed three rounds of PCR with pro11 and the M13 primer RV (first round) and pro12 and pro6 (second round) using a 0.6-kb fragment from the pBluescript SK Ϫ vector for template. After these PCR, the PCR fragments were diluted and mixed, and the third round PCR was performed using the M13 primer RV and pro6 primers. We also performed three rounds of PCR to generate constructs lacking the vitamin D response element (VDRE)-like motif (VLM): for pGL/⌬VLM-1, the first round of PCR was carried out using the M13 primer RV and pro14, and the second round with pro6 and pro15 using a 0.6-kb fragment from the pBluescript SK Ϫ vector for template; and for pGL/⌬VLM-2, the first round of PCR was carried out using primer pro16 and pro17 using a 0.6-kb fragment from the pBluescript SK Ϫ vector for template. The third round PCR was performed using the M13 primer RV and pro6 primers. The fragments were digested with SacI and HindIII and then inserted in the pGL3 basic vector. All constructs were confirmed by sequencing on both strands.
Transient transfection and functional promoter analysis. K-562, Hep G2, and MC3T3-E1 cells were cultured in 24-well plates in culture medium without antibiotics. After 24 h (when cells reached 80 -90% confluence), liposome-mediated transfection was performed. Promoter vector DNA (1 g), 0.05 g of phRL-TK (Renilla luciferase reporter construct used as an internal standard; Promega), and 4 l Lipofectamine2000 (Invitrogen) were mixed with 100 l of Opti-MEM medium (Invitrogen) for 15 min at room temperature. The mixture was then added to the cells and incubated for 48 h, after which the cells were harvested for reporter gene assays. Promoter reporter assays were performed using the Dual Luciferase assay kit (Promega) according to the manufacturer's instructions. Luciferase activities were measured with a Lumat LB9507 luminometer (Berthold Detection Systems, Pforzheim, Germany), and all assays provided data that were well within the linear range of the instrument. The experiments were performed in triplicate wells and were repeated at least three times.
For studies related to the effect of phosphate concentration, the K-562 cells were plated in 24-well plates in triplicate wells, and the cells were kept for 24 h in appropriate medium containing 10% FCS and without antibiotics. Subsequently, cultured cells were transfected with the plasmid constructs and incubation for 4 h, followed by the addition of hormones or phosphate. To determine the effects of hormones, the cells were incubated for 24 h in 1,25(OH)2D3 (10 Ϫ9 to 10 Ϫ6 M) or in vehicle in Ham's F-12 medium containing 10% charcoal-treated FCS. The cells were then harvested for reporter gene assays. For studies of the effect of different phosphate concentrations, the cells were kept in phosphate-free DMEM (Invitrogen) supplemented with 0.1, 0.9, or 1.5 mM Na2HPO4-NaH2PO4 (pH 7.4) or in Ham's F-12 medium containing 1 mM phosphate supplemented to 3 or 6 mM phosphate and then incubated with for 24 h in 10 Ϫ8 M 1,25(OH)2D3. To determine the effect of different concentrations of calcium, cells were kept in Ham's F-12 medium containing 0.3 mM calcium supplemented to 1 or 6 mM with CaCl2 and then incubated for 24 h with 10 Ϫ8 M 1,25(OH)2D3. Quantitative real-time PCR for endogenous FGF-23 gene expression. K-562 cells were treated for 24 h with 10 Ϫ8 M 1,25(OH)2D3 in high-phosphate or normal growth medium. The cDNA synthesized from 1 g of total RNA was used for real-time PCR (LightCycler; Roche Diagnostics, Indianapolis, IN) using a QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA). Each sample was analyzed in triplicate. For amplification of a 147-bp fragment of the FGF-23, the primers (hFGF23-p3 and 5Ј-TCCAGCGTCTGGTGTTGGAAC-3Ј) were used. The mRNA levels were normalized to the GAPDH mRNA level. Primers for amplification of a 114-bp GAPDH fragment were the GAPDH forward primer and 5Ј-CTTCTGGGTGGCAGTGAT-GGC-3Ј (reverse 2), and the annealing temperature was set at 55°C.
Cotransfection and detection of endogenous VDR. The human VDR (hVDR) expression vector pSG5/hVDR (2) was used for cotransfection experiments. The pSG5 empty vector (Invitrogen) was used for control experiments. After 24 h (when cells reached 80 -90% confluence), cells were transfected for 4 h with 1 g promoter vector DNA, 0.05 g phRL-TK, and 0.2 g pSG5/hVDR using Lipofectamine2000. Next, cells were treated for 24 h with phosphate, calcium, and/or 1,25(OH)2D3 and then harvested for reporter gene promoter assays. Gene expression of VDR was analyzed by real-time PCR. Primer sequences (5Ј-GTGGGACTGAAGAAGCTGAAC-3Ј and 5Ј-TGTGTTGGACAGGCGGTCCTG-3Ј) for amplification of a 135-bp fragment of the VDR were generated based on GenBank sequence number J03258.
Detection of plasma FGF-23. The plasma concentration of the endogenous FGF-23 (mouse) was determined using a FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan).
Statistical analysis. Results are reported as means Ϯ SE for at least three samples. The statistical significance of differences between measured values was determined by ANOVA using GraphPad InStat (GraphPad Software, San Diego, CA). Kinetic parameters of uptake were determined by linear regression analysis of Lineweaver-Burk plots.
RESULTS

Isolation and structure of the mouse FGF-23 5Ј-flanking region.
The mouse FGF-23 gene was cloned and characterized using PCR and the primers listed in Table 1 . Primer sequences were derived from the mouse FGF-23 cDNA sequences (GenBank accession no. NM_022657). The transcription initiation site of the mouse FGF-23 gene was determined by 5Ј-RACE (data not shown). The 5Ј-flanking DNA sequence (ϳ1400 nucleotides) is shown in Fig. 1 and was analyzed for putative trans-acting factor binding sites using the TFSEARCH program (http://mbs.cbrc.jp/research/db/TFSEARCH.html). The promoter region of the mouse and human FGF-23 gene has ϳ58% identity (data not shown). There are two highly conserved regions in the promoter region of the mouse FGF-23 promoter, one of which is a classic TATA-like box (TFIIDbinding element). The TATA-like box was identified 27 bp upstream of the transcription start site and is located at a similar position within the human FGF-23 promoter. However, neither AP1 or Sp1 binding sites nor glucocorticoid T 3 or VDRE were found. However, the 1.4-kb FGF-23 promoter fragment contains a number of MZF-1, GATA-1, GATA-2, and C-Ets-1 motifs that are recognized by well-characterized transcription factors in lymphocytes and T cells.
Cell specificity and abundance of FGF-23 mRNA. Before proceeding with the functional analysis of the 5Ј-flanking region of the FGF-23 gene, we identified cells expressing or lacking FGF-23 mRNA. Recent reports, largely based on RT-PCR analysis, suggest that FGF-23 is produced in liver, lymph nodes, thymus, heart, K-562, and Raji cell lines (28, 31, 34) . We confirmed expression in the cell lines by nested-PCR analysis using various primers (Table 2 and Fig. 2A) . We detected FGF-23 mRNA expression in the human leukemia cell line K-562 but failed to detect FGF-23 transcripts in Hep G2 and Raji cells (Fig. 2B) . We also examined the expression of FGF-23 in other cell lines, including primary osteoblasts derived from mouse calvaria, MC3T3-E1, ST2, and Saos-2 cells, but failed to detect it (data not shown).
Functional characterization of the FGF-23 promoter in K-562 cells. To investigate the transcription of the FGF-23
gene, we evaluated the effect of several deletions of the FGF-23-luciferase promoter constructs in K-562 cells (Fig. 3) . Progressive 5Ј-deletion mutants of the promoter revealed a bimodal pattern of functional activity in transiently transfected K-562 cells (Fig. 3) . The pGL/Ϫ0.6 promoter construct (Ϫ554 to ϩ98) caused a nearly a sixfold increase in FGF-23 mRNA expression K-562 cells. Progressive 5Ј-deletions relative to the transcription start side caused a gradual reduction in promoter activity. Further deletions from Ϫ1430 to Ϫ554 bp, however, led to an increase in promoter activity, although it did not exceed the activity of the pGL/Ϫ0.6 promoter. Successive results of the second PCR. FGF-23 was detected in K-562 cells using all primer combinations but not in any of the other cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as control for RNA integrity (bottom). M, 100-bp ladder marker; H, Hep G2; R, Raji; K, K-562; n, without template as a negative control. deletions from Ϫ128 bp (pGL/Ϫ0.13) lead to a clear reduction in promoter activity in K-562 cells, resulting in a level activity close to that of the basic plasmid alone.
To elucidate whether the two motifs from Ϫ275 bp to Ϫ256 bp (C-Ets-1 and MZF-1) are essential for promoter activity, we examined the activity of deletion mutant pGL/Ϫ0.3 (Ϫ246 to ϩ98) and pGL/⌬MC constructs lacking only the two motif sequences in pGL/Ϫ0.6 (Fig. 4) . The promoter activities of these deletion mutants were lower than that observed with pGL/Ϫ0.6. These results suggested that the two motifs are important for promoter activity in K-562 cells. The construct with a 10-bp deletion lacked the TATA-like box (pGL/⌬TATA) in pGL/Ϫ0.6 and had luciferase activity that was the same as the basic plasmid alone, suggesting that it functions as a TFIIDbinding element.
We next examined the specificity of the FGF-23 promoter activity in Hep G2, Raji, and osteoblastic MC3T3-E1 cells (data not shown). Although the various FGF-23 promoter constructs were transiently transfected in cells, promoter activity was not detected. These findings were consistent with the results of the RT-PCR and suggested that the promoter activities in K-562 are specifically regulated.
Effect of phosphate-and calcium-regulating hormone on FGF-23 promoter activity. We used a transient expression assay to determine whether 1,25(OH) 2 D 3 enhance FGF-23 gene promoter (pGL/Ϫ0.6) activity in K-562 cells (Fig. 5A) . Transfected cells were treated with 1,25(OH) 2 D 3 at a dose ranging from 10 Ϫ9 to 10 Ϫ6 M, and luciferase activity was recorded after 24 h. We observed a dose-dependent effect of 1,25(OH) 2 D 3 to increase luciferase activity in K-562 cells transfected with pGL/Ϫ0.6.
The VDRE consensus sequence (A/GGG/TTCA/G nng A/GGTTCA/G, where n is optional nucleotide) was not found in the 1.4-kb FGF-23 promoter region (Fig. 1 ), but there were two similar VDRE half-site regions (VLM1 and VLM2) between Ϫ275 and Ϫ182. To test whether these motifs function as VDREs, deletion constructs for VLM1 and VLM2 were transfected, and then their response to 1,25(OH) 2 D 3 was examined. As shown in Fig. 5B , the two constructs still responded to 1,25(OH) 2 D 3 in high-phosphate medium.
Effect of phosphate concentration on FGF-23 promoter activity. To test whether phosphate level regulates FGF-23 expression, we assayed the promoter activity at different phosphate concentrations in the medium. High-phosphate (3 mM) medium caused a significant increase (1.7-fold) in the promoter activity of pGL/Ϫ0.6 (Fig. 6A) . The FGF-23 promoter did not respond to low-phosphate (0.1 mM) or normal phosphate (1.5 mM) medium (data not shown). In addition, FGF-23 promoter activity was increased 2.7-fold after treatment with 10 Ϫ8 M 1,25(OH) 2 D 3 in the presence of 1.0 mM phosphate, and it Fig. 4 . Deletion analyses of the TATA-like box and c-Ets-1/MZF1 motif. The pGL/Ϫ0.3 constructs do not contain the C-Ets-1 and MZF1 motifs located between Ϫ275 and Ϫ256. These motifs were deleted from pGL/Ϫ0.6 (pGL/⌬MC). The pGL/⌬TATA plasmid has a 10-bp deletion of the TATA-like box sequence from pGL/Ϫ0.6. These constructs were transfected into K-562 cells, and luciferase activity was analyzed. Luciferase activity was compared related to pGL3 basic vector alone and is expressed as a ratio to Renilla luciferase activity to correct for transfection efficiency. Values represent means Ϯ SE from 6 separate experiments. *P Ͻ 0.05 for various constructs vs. the basic plasmid alone. (Fig. 6B) . The quantitative real-time PCR analysis clearly showed that the abundance of FGF-23 mRNA was significantly increased (3.3-fold) in 1,25(OH) 2 D 3 -treated cells in the presence of 3 mM phosphate, but there was no change in 6 mM phosphate (Fig. 6C) . Also, there was no change in GAPDH mRNA abundance upon treatment with vehicle or 1,25(OH) 2 D 3 in high-phosphate medium. To test whether calcium affects FGF-23 promoter activity, we assayed the promoter activity in medium containing 0.3-5 mM CaCl 2 (data not shown). The promoter activity of FGF-23 was unaffected in this range of calcium concentrations, and calcium had no synergic effect in combination with 1,25(OH) 2 D 3 (Fig. 7) .
Activation of VDR dependent on FGF-23 promoter. To test whether exogenous VDR affects FGF-23 promoter activity, we examined the effect of cotransfection of hVDR and FGF-23 promoter construct pGL/Ϫ0.6 in K-562 cells (Fig. 8A) . Enhancement of promoter activity with 1,25(OH) 2 D 3 was greater when VDR was cotransfected. This suggests that elevation of VDR stimulates FGF-23 promoter activity.
We next examined whether 1,25(OH) 2 D 3 and phosphate affect the level of the VDR mRNA. As shown in Fig. 8B , endogenous VDR levels were stimulated by addition of 1,25(OH) 2 D 3 but not by the addition of phosphate. These results suggested that the cellular VDR levels are an important determinant of FGF-23 promoter activity. In contrast, the synergic effect of phosphate and 1,25(OH) 2 D 3 was not dependent of the level of the VDR . 
Effect of dietary phosphate on the levels of plasma FGF-23 in vivo.
To further investigate whether dietary phosphate affects the levels of plasma FGF-23 in normal mice, we measured the concentration of plasma FGF-23 in low (0.02%), normal (0.6%), and high (1.2%) inorganic phosphate diets. The plasma phosphate levels were decreased in mice fed a lowphosphate diet (3.5 Ϯ 0.4 mg/dl) and increased in mice fed a high-phosphate diet (9.8 Ϯ 2.1 mg/dl). Moreover, as shown in Fig. 9A , the levels of plasma FGF-23 were significantly increased in mice fed a high-phosphate diet compared with those receiving normal and low-phosphate diets. In contrast, the levels of plasma FGF-23 in mice fed a low-phosphate diet were significantly decreased compared with those receiving the normal phosphate diet.
Effect of plasma FGF-23 on the VDR knockout mice in vivo. Finally, we examined the levels of FGF-23 in VDR knockout mice (VDR-KO). VDR-KO mice displayed hypophosphatemia and hypocalcemia as described previously (10, 36) . As shown in Fig. 9B , the levels of plasma FGF-23 in 8-wk-old VDR-KO mice were significantly decreased compared with in the levels in wild-type mice.
DISCUSSION
In the present study, we characterized the 5Ј-flanking region of the mouse FGF-23 and indicated the regulation by phosphate and 1,25(OH) 2 D 3 . FGF-23 is overexpressed in several tumors that cause TIO. In TIO patients, the most frequent histological diagnosis has been in mesenchymal tissues, such as in hemangiopercytomas, mesenchymal tumors with vascular elements, epidermal naevi, osteosarcomas, and chondrosarcomas (14, 20, 30) . K-562 is a human erythroleukemic cell line derived from human chronic myelogenous leukemia and the proliferation of erythroid progenitor cells in human bone marrow culture. The leukemias are now also considered to be angiogenesis-dependent malignancies (1). Thus we suggest that the regulation of expression and physiological roles of FGF-23 in erythroleukemia K-562 cells can provide new insights into the homeostatic control of phosphate metabolism.
Plasma FGF-23 levels were increased in mice fed a highphosphate diet, and the FGF-23 promoter activity was upregulated in high-phosphate medium containing 1,25(OH) 2 D 3 . This is the first report that dietary phosphate affects the levels of plasma FGF-23 and that phosphate in the medium affects the transcription of the FGF-23 gene. A connection between phosphate levels and FGF-23 has also been shown in mutant mice lacking FGF-23, which exhibit severe hyperphosphatemia, and in transgenic FGF-23 animals, which show hypophosphatemia (27, 29) . In the present study, we further demonstrated that plasma phosphate levels are important regulators of the transcription via the FGF-23 gene promoter.
In a previous study, we identified the phosphate-responsive element (PRE) of the human type IIa Na-P i cotransporter gene (12, 17) . The corresponding DNA-binding protein was identified as the transcription factor TFE3. In this study, we showed that a low-phosphate diet increases the transcription of the type IIa Na-P i cotransporter gene and that TFE3 binds the PRE in Fig. 8 . Effect of vitamin D receptor (VDR) expression on FGF-23 gene regulation. The human VDR expression vector pSG5/hVDR was cotransfected with pGL/ Ϫ0.6 into K-562 cells. The pSG5 empty vector was used for control experiments. A: after 4 h, 1,25(OH)2D3 was added in normal medium, and, 24 h later, cells were harvested for reporter gene promoter assays. B: after transfection, phosphate and 1,25(OH)2D3 were added to normal medium, and, 24 h later, cells were collected and total RNA was extracted. The level of VDR mRNA (135-bp fragment) was determined using real-time PCR. The mRNA levels were normalized to the level of GAPDH mRNA. Each sample was analyzed in triplicate. *P Ͻ 0.05. the type IIa Na-P i cotransporter gene (12, 17) . However, in the current study, the PRE was not detected in the mouse FGF-23 gene promoter region. Other reports demonstrated that phosphate can act as a signaling molecule capable of altering gene expression in osteoblast development, which prompted us to conduct a microarray analysis of phosphate-treated osteoblasts (4, 5). Beck et al. (5) showed that the basic region leucine zipper transcription factor Nrf2 (NF-E2-related factor 2) was upregulated in the osteoblast response to the high-phosphate medium. We found several binding motifs for leucine In the promoter region of the mouse FGF-23 gene, we did not find the consensus VDRE. In K-562 cells cotransfected with VDR and FGF-23 promoter construct pGL/Ϫ0.6, 1,25(OH) 2 D 3 markedly increased the activity of the mouse FGF-23 promoter. Indeed, the levels of plasma FGF-23 in the VDR-KO mice were significantly lower than in wild-type mice. Thus the upregulation of the FGF-23 promoter by 1,25(OH) 2 D 3 may be because of the presence of cellular VDR.
The FGF-23 promoter activity was also upregulated by high phosphate and 1,25(OH) 2 D 3 ; however, high phosphate alone did not increase the activity. These results suggested that the activation of FGF-23 promoter was regulated by phosphate and 1,25(OH) 2 D 3 but that the activation pathways may be different. For the 24-OHase gene promoter, the action of 1,25(OH) 2 D 3 is mediated by Ras-dependent activation of ERK1/ERK2 and ERK5 (7). The 24-OHase promoter has two VDREs and an Ets-1 binding site. The induction of the 24-OHase expression by 1,25(OH) 2 D 3 is mediated by ERK5 phosphorylation of Ets-1. We found two c-Ets-1-binding motifs in the mouse FGF-23 promoter region. Therefore, the activation of the FGF-23 promoter by vitamin D may be mediated by the ERK/ERK2 and ERK5 signal pathway. A recent report indicates that the regulation of osteopontin expression by inorganic phosphate is mediated by ERK1/2 and protein kinase C signaling pathways (4). These results suggest that high phosphate affects the activity of the VDR, but further studies are needed to clarify the regulation of the VDR by 1,25(OH) 2 D 3 and phosphate.
Several recent studies have demonstrated that FGF-23 is an important factor in vitamin D metabolism (15, 22, 27, 29) . Injection of FGF-23 in mice reduces 1,25(OH) 2 D 3 in plasma (26, 29) . In FGF-23 null mice, Shimada et al. (27) showed that there is an elevation in plasma 1,25(OH) 2 PTH is also well known as a phosphate-regulating hormone that inhibits renal phosphate reabsorption by affecting the type IIa Na-P i cotransporter and by indirectly increasing intestinal phosphate absorption by stimulating the synthesis of 1,25(OH) 2 D 3 (11, 19) . In renal proximal tubules, long-term treatment (5-9 h) with PTH causes downregulation of FGF-23 (26) , but the type IIa Na-P i cotransporter proteins are decreased within 2 h (11, 19) . Therefore, FGF-23 seems to participate in a PTH-independent pathway (26) .
In summary, we demonstrated that vitamin D and plasma phosphate are important regulators of the transcription of the mouse FGF-23 gene. These two factors have a synergistic effect on FGF-23 expression. Further studies are needed to clarify the physiological roles of FGF-23 expression in erythroleukemic cell lines.
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